Bellicum Pharmaceuticals (MUN:BPXA) - Stock Price, News & Analysis

BPXA Stock Overview

BPXA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Does not have a meaningful market cap (€772K)

Shares are highly illiquid

Does not have meaningful revenue ($2M)

Bellicum Pharmaceuticals, Inc. Competitors

Sangui Biotech International

HMSE:SBH

€419.8k

Epigenomics

DB:ECX

€1.1m

co.don

XTRA:CNW

€6.5m

Paion

DB:PA8K

€44.2k

Price History & Performance

Summary of all time highs, changes and price drops for Bellicum Pharmaceuticals
Historical stock prices
Current Share Price	€0.06
52 Week High	€0.06
52 Week Low	€0.06
Beta	1.38
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	BPXA	DE Biotechs	DE Market
7D	0%	-0.2%	0.8%
1Y	n/a	-16.9%	9.1%

Return vs Industry: Insufficient data to determine how BPXA performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how BPXA performed against the German Market.

Price Volatility

Is BPXA's price volatile compared to industry and market?
BPXA volatility
BPXA Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: BPXA has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BPXA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2004	13	Dave Maggio	www.bellicum.com

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company’s clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen.

Bellicum Pharmaceuticals, Inc. Fundamentals Summary

How do Bellicum Pharmaceuticals's earnings and revenue compare to its market cap?
BPXA fundamental statistics
Market cap	€772.38k
Earnings (TTM)	-€21.01m
Revenue (TTM)	€1.42m

0.5x

P/S Ratio

0.0x

P/E Ratio

Is BPXA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BPXA income statement (TTM)
Revenue	US$1.51m
Cost of Revenue	US$18.63m
Gross Profit	-US$17.12m
Other Expenses	US$5.26m
Earnings	-US$22.38m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.84
Gross Margin	-1,135.08%
Net Profit Margin	-1,483.95%
Debt/Equity Ratio	0%

How did BPXA perform over the long term?

See historical performance and comparison